A new study published by Cleveland Clinic researchers in Diabetes, Obesity and Metabolism investigating the genetic underpinnings of weight loss response has identified a gene, neurobeachin (NBEA), as a predictor of how individuals respond to GLP-1RAs, the class of medications behind popular treatments like liraglutide and semaglutide.
This article was originally published on MedicalXpress.com